After the visit
Pause when the answers do not fit.
An answer that cannot be checked is a reason to pause and ask again.
Pause at a missing prescription.
Dispensing a prescription drug without a valid prescription breaks federal law, as of September 2026.
Ask how the assessment and prescription step work. A product checkout is not an answer to that question.
Pause at a false approval claim.
The U.S. Food and Drug Administration is called the FDA.
Medicine prepared to order is called compounded medicine.
Compounded medicines have no FDA approval, so a claim of that approval is false, as of September 2026.
Request the precise product name and the source supporting the claim.
The FDA also calls it misleading to claim that a compounded medicine matches an approved product.
Pause when the source is unclear.
Semaglutide is in Ozempic and Wegovy. Tirzepatide is in Mounjaro and Zepbound.
As of September 2026, the FDA has documented false pharmacy information on some compounded semaglutide and tirzepatide labels.
Ask for the pharmacy’s actual name and check the state record before proceeding.
If a label and the written answer differ, ask the pharmacy to explain the mismatch.
Keep price in context.
The FDA lists unusually deep discounts as a sign to examine alongside other pharmacy checks.
A low price alone does not prove that an offer is improper.
Return to the missing answer: who treats you, which medicine is offered, which pharmacy makes it, or what the terms are. Ask again before deciding.
Take the unanswered questions to a visit →Sources behind this check
The FDA’s checks address prescriptions, sourcing, and claims. Check the full picture rather than one signal.